Published by Coherent Market Insights
Posted on September 29, 2021
5 min readLast updated: February 1, 2026
The Allergic Rhinitis Drugs Market is set to grow to $17.8Bn by 2027, driven by increasing prevalence and new treatments.
The Allergic Rhinitis Drugs Market has witnessed continuous growth in the past few years and is projected to grow even further during the forecast period (2021-2027). The research presents a complete assessment of the market and contains Future trend, Current Growth Factors, attentive opinions, facts, historical data, and statistically supported and industry validated market data.
Allergic Rhinitis Drugs Market report presents the detail analysis of the parent market based on elite players, present, past and futuristic data which will serve as a profitable guide for all the industry competitors. Key players in the Allergic Rhinitis Drugs market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All measurement shares, splits, and breakdowns have been resolute using secondary sources and verified primary sources. The Market report begins with a basic overview of the industry lifecycle, definitions, classifications, applications, and industry chain structure and all these together will help leading players understand scope of the Market, what characteristics it offers and how it will fulfill customer’s requirements.
Click Here To Get Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/1201
Allergic rhinitis, also called hay fever, is an allergic reaction that causes sneezing, congestion, itchy nose, and sore throat. It is triggered by breathing in tiny particles of allergens. The most common airborne allergens that cause rhinitis are pollen and spores, dust mites, urine/saliva, and animal skin. Symptoms can also occur when eating a food to which individuals are allergic. Allergic rhinitis treatment consists of self-care and antihistamines.
Antihistamines, drugs used to treat hay fever and other allergies, can reduce symptoms. Many other drugs, such as fexofenadine (Allegra), diphenhydramine (Benadryl), loratadine (Claritin), desloratadine (Clarinex), levocetirizine (Xyzal), and cetirizine (Zyrtec), are also used to treat allergic rhinitis. They can significantly reduce nasal congestion as well as sneezing, itching, and a runny nose. Thus, there is an increasing demand for allergic rhinitis drugs worldwide.
Key Market Drivers:
Increasing prevalence of allergic rhinitis across the world is expected to augment the growth of the allergic rhinitis drugs market during the forecast period. For instance, according to the World Allergy Organization (WAO), more than 400 million people suffer from allergic rhinitis worldwide, which to a large extent remains underdiagnosed and undertreated.
Moreover, continuous research and development in allergic rhinitis and introduction of novel allergic rhinitis treatment is expected to boost the growth of the allergic rhinitis drugs market. For instance, the U.S. Food and Drug Administration (UFDA) approved ALK’s RAGWITEK (Short Ragweed Pollen Allergen Extract) Tablet for the treatment of patients aged 5 to 65 years with short ragweed pollen-induced allergic rhinitis.
COVID-19 Impact Analysis:
With the larger part of the population confined indoors due to the pandemic, indoor pollution has become an increasing concern, leading to a rise in allergic rhinitis cases. However, allergic rhinitis did not affect the severity of COVID-19, but there is always a risk of infection. COVID-19 affects different people in different ways. Thus, there is an increasing demand for safe and effective hospitalize treatment worldwide, driving the allergic rhinitis drugs market growth. Most people develop mild to moderate illness and recover without hospitalization, while some people need to be hospitalized.
Key Takeaways:
The allergic rhinitis drugs market is expected to exhibit a CAGR of XX % during the forecast period owing to high incidence of asthma worldwide. Asthma is the most common chronic disease among children. For instance, according to the World Health Organization (WHO), in 2019, asthma affected an estimated 262 million people worldwide and caused 461000 deaths.
Among regions, Asia Pacific is expected to witness a strong growth in the allergic rhinitis drugs market due to the increasing prevalence of allergic rhinitis and asthma in this region. According to the National Center for Biotechnology Information, around 20 to 30 % of the Indian population suffers from allergic rhinitis and that 15 % develop asthma. Moreover, in June 2020, Cadila Pharmaceuticals launched Bilastine syrup and Bilastine tablets for the treatment of allergic rhinitis.
North America is also expected to witness significant growth in the allergic rhinitis drugs market due to high incidence of allergic rhinitis. For instance, according to WAO, allergic rhinitis affects between 10-30% of the U.S. population and up to 40% of children, making it the fifth most common chronic disease.
What Allergic Rhinitis Drugs Market report offers:
Major Players Analysed The Market
These Players Are: Merck & Co., Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline PLC, Sanofi S.A., Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Alcon (Novartis AG), Unichem Laboratories, Mylan, ALK, Innovus Pharmaceuticals, Inc., and Glenmark Pharmaceuticals Ltd.
Remarkable Attributes of Allergic Rhinitis Drugs Market Report:
Buy This Research Study Report For Quick Access with flat US $ 2000 off@ https://www.coherentmarketinsights.com/promo/buynow/1201
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
The post Allergic Rhinitis Drugs Market Is Projected to Be Around US$ 17,863.6 Mn With Healthy CAGR of 3.6% by 2027 appeared first on Gatorledger.
The article discusses the growth and trends of the Allergic Rhinitis Drugs Market projected to 2027.
COVID-19 has increased indoor pollution concerns, raising demand for rhinitis drugs.
Increasing prevalence of allergic rhinitis and new treatment approvals are key growth drivers.
Explore more articles in the Research Reports category
